Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)
Keywords:
Corrigendum
Cellular medicaments
Cell-based therapy
Clinical trials
Diabetes
Critical limb ischemia
Cost-effectiv
Publisher:
Frontiers Media
Note:
This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that
the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does
not comply with these terms.
Citation:
Soria-Juan, B. (Bárbara); Escacena, N. (Natalia); Capilla-González, V. (Vivian); et al. "Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)". Frontiers in immunology. 11, 2020, 2029
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.